HANSOH PHARMA (03692.HK): Socrodeucitinib NDA accepted by NMPA for psoriasis

On Nov 20, 2026, HANSOH PHARMA said the NDA for its self-developed Socrodeucitinib Tablets (HS-10374) was accepted by China's NMPA for adults with moderate-to-severe plaque psoriasis.

NewTimeSpace News: On November 20, 2026, HANSOH PHARMA (03692.HK) announced that the new drug application (NDA) for its innovative medicine Socrodeucitinib Tablets (HS-10374 Tablets) has been accepted by China's National Medical Products Administration (NMPA) for adult patients with moderate-to-severe plaque psoriasis.

According to the announcement, Socrodeucitinib Tablets is a selective allosteric inhibitor of tyrosine kinase 2 (TYK2) self-developed by the Group, and the indication filed this time is moderate-to-severe plaque psoriasis in adults. Following acceptance, the product remains subject to the NMPA's review and approval procedures, and the announcement was published on a voluntary basis.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.